We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Mesoblast Limited is one of them. Mesoblast Limited (NASDAQ:MESO) is a global leader in developing allogeneic, off-the-shelf cellular medicines for inflammatory diseases. Using its proprietary mesenchymal lineage cell platform, the company targets severe and life-threatening conditions by modulating immune responses and promoting tissue repair. Its lead product, Ryoncil® (remestemcel-L), recently became the first FDA-appr ...